OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 551 - 560 of 763 studies

Reproductive health and childbirth

A Phase 2, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of 2 doses of vipoglanstat in patients with moderate to severe endometriosis-related pain – the NOVA trial (The NOVA trial)

Cancer and neoplasms

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Understanding adherence to weekly growth hormone treatment: A mixed-methods observational longitudinal study.

Neurological

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)

Oral and Gastrointestinal

A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study With An Active Treatment Extension To Assess The Efficacy, Safety, And Pharmakokinetics Of Ro7837195 In Patients With Moderately To Severely Active Ulcerative Colitis (GA45977 (SUNCREST))

Cancer and neoplasms

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

A prospective, real-world registry of acute myeloid leukaemia patients in the United Kingdom

Cancer and neoplasms

An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer

Cancer and neoplasms

A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

In vivo investigation of immune dynamics following cutaneous challenge (VIVID)